Skip to main content

Animations

MJFF Publications

5901 - 5910 of 9033 Results
Title
Year
  • Year
  • 2022
  • 2017
  • 2006
  • 2023
  • 2021
  • 2019
  • 2021
  • 2020
  • 2026
  • 2018
  • Summary Details
    OPEN
    Title: The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
    Journal Name: Disease Models & Mechanisms
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1242/dmm.049192
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
    Journal Name: Journal of Neuroinflammation
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12974-017-0935-1
    Citation Count: 105
  • Crossroads in GDNF therapy for Parkinson's disease
    2006
    Summary Details
    RESTRICTED
    Title: Crossroads in GDNF therapy for Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.20861
    Citation Count: 174
  • Summary Details
    OPEN
    Title: Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease
    Journal Name: Communications Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s43856-023-00294-w
    Citation Count: 42
  • Summary Details
    OPEN
    Title: Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials
    Journal Name: Journal of Participatory Medicine
    Publisher: JMIR Publications Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.2196/31371
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.27806
    Citation Count: 139
  • Summary Details
    OPEN
    Title: Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.28608
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Lack of evidence for genetic association of saposins A, B, C and D with Parkinson’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awaa214
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α‐Synuclein Status in Sporadic and Genetic Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.70186
    Citation Count: 2
  • At last, a randomised controlled trial of apomorphine infusion
    2018
    Summary Details
    RESTRICTED
    Title: At last, a randomised controlled trial of apomorphine infusion
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30284-9
    Citation Count: 3
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.